Browse > Article
http://dx.doi.org/10.5487/TR.2007.23.2.159

Toxicity Screening After Single Dose of a Newly Developed Oral Heparin Derivative in Male Cynomolgus Monkeys  

Kim, Choong-Yong (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT)
Kim, Sang-Kyoon (Department of Materials Science and Engineering, Gwangju Institute of Science and Technology)
Woo, Young-Ah (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT)
Jeong, Eun-Ju (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT)
Han, Su-Cheol (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT)
Heo, Jeong-Doo (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT)
Park, Kui-Lea (National Institute of Toxicological Research)
Byun, Young-Ro (College of Pharmacy, Seoul National University)
Publication Information
Toxicological Research / v.23, no.2, 2007 , pp. 159-164 More about this Journal
Abstract
Toxicity screening of a newly developed oral heparin derivative were carried out in 6 male cynomolgus monkeys (Macaca fascicularis), composed of a treatment group and vehicle control group. A newly orally active heparin derivative, developed by Seoul National University, was once given to treatment group at dose of 500 mg/kg. A treatment group did not show any change in body weights, hematological parameters including platelet-related varivables (platelet, PDW, PCT, MPV) and serum biochemical parameters (e.g., AST, ALT, BUN, etc.) for 2 weeks compared with those of vehicle control group. We also confirmed the maximum plasma concentration (Cmax, 1.73 IU/ml) and the time (Tmax, 1 hr) to reach Cmax. The present study will be valuable in the proper interpretation for nonclinical study using cynomolgus monkeys in the development of new drug of heparin derivative.
Keywords
Cynomolgus monkeys; Oral heparin derivative; Toxicity screening;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gonze, M.D., Salartash, K., Sternbergh III, W.C., Baughman R.A., Leone-Bay, A. and Money, S.R. (2000). Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation, 101, 2658-2661   DOI   ScienceOn
2 Malkov, D., Wang, H., Dinh, S., Steven, D. and Gomez-Orellana, I. (2002). Pathway of oral absorption of heparin with sodium N-(8-(2 hydroxybenzoyl)amino) caprylate. Pharm. Res.. 19, 1180-1184   DOI   ScienceOn
3 김충용, 이현숙, 한수철, 허정두, 하창수, 권명상, 정문구 (2004). Cynomolgus monkey에 있어 혈액학 및 혈액생화학적 지표. 한국실험동물학회지, 20, 44-48
4 Lee, Y.K., Kim, S.K., Lee, D.Y., Lee, S., Kim, C.Y., Shin, H.C. and Moon, H.T. (2006). Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J. Control Release, 111, 290-298   DOI   ScienceOn
5 Mark, D.G., Jeffrey, D.M. and Andrea, L.B. (1998). Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg., 176, 176-178
6 Menajovsky, L.B. (2005). Heparin-induced thrombocytopenia: clinical manifestations and management. Am. J. Med., 118(Suppl. 8A), 21S-30S
7 Aken, H.V., Bode, C.B., Darius, H., Diehm, C., Encke, A., Gulba, D.C., Haas, S., Haccke, W., Puhl, W., Quante, M., Riess, H., Scharf, R., Schellong, S., Schror, K., Schulte, K.-L. and Tebbe, U. (2001). Anticoagulation: The present and future. Clin. Appl. Thrombo. Hemost., 7, 195-204   DOI   ScienceOn
8 정영미 (2006). 항응고제치료에 사용되는 약물. 병원약사회지, 23, 5-11
9 Wolford, S.T., Schroer, R.A., Gohs, F.X., Gallo, P.P., Brodeck, M., Falk, H.B. and Ruhren, R.R. (1986). Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Heal., 18, 161- 188   DOI   ScienceOn
10 Strandness, D.E. Jr. (2001). Anticoagulant therapy: Current status and shortcomings. Seminars in Interventional Radiology, 18, 113-118
11 Cines, D.B., Rauova, L., Arepally, G., Reilly, M.P., McKenzie, S.E., Sachais, B.S. and Poncz, M. (2007). Heparininduced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher., 22, 31-36   DOI   ScienceOn
12 Kim, S.K., Vaishali, B., Lee, E., Lee, S., Lee, Y.K., Kumar, T.S., Moon, H.T. and Byun, Y. (2006). Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res., 117, 419-427   DOI   ScienceOn
13 Lee, Y., Moon, H.T. and Byun, Y. (1998). Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res., 92, 149-156   DOI   ScienceOn
14 Ginsberg, J.S. (1999). Thromboembolism and pregnancy. Thromb. Haemost., 82, 620-625   DOI
15 Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G. and McLaughlin, D. (1982). Adjusted subcutaneous heparin versus warfarin sodium in the longterm treatment of venous thrombosis. N. Engl. J. Med., 306, 189-194   DOI   ScienceOn
16 Lee, Y., Nam, J.H., Shin, H.C. and Byun, Y. (2001). Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation, 104, 3116-3120   DOI   ScienceOn
17 Hirsh, J. and Fuster, V. (1994). Guide to anticoagulant therapy, Part 1: heparin. Circulation, 89, 14449-1468
18 Hirsh, J. (2003). Current anticoagulant therapy-unmet clinical needs. Throm. Res., 109, S1-S8   DOI   ScienceOn
19 Alpert, J.S. and Dalen, J.E. (1994). Epidemiology and natural history of venous thromboembolism. Prog. Cardiovasc. Dis., 36, 417-422   DOI   ScienceOn